Family Planning Through Dairy Cooperatives
Providing Family Planning Services Sustainably Through Dairy Cooperatives in Kenya
Studieoversikt
Status
Status
Forhold
Forhold
Detaljert beskrivelse
Access to family planning and other reproductive health services remains difficult in much of rural Kenya. One option for improving rural access to family planning is to use existing community events outside of the health sector as platforms for delivering information and services. This study will assess a model for providing family planning through quarterly events organized by dairy cooperatives supported by Land O'Lakes in Kenya. During these events, known as Field Days, a healthcare provider will have a tent in which Field Day attendees can receive basic family health services free of charge. The services offered will be: family planning counseling and methods, immunizations, antenatal care, screening and treatment for sexually transmitted infections, and HIV counseling and testing. Since the services are no different than those that could be obtained at Ministry of Health or some private facilities, the service provision is not considered to be part of the research.
Women receiving any service from the health care provider will be recruited for an interview that will measure their demand for family planning and attitudes about receiving services during the field day. In addition, the study will track the number of different types of services provided, the total number of Field Day attendees, and the cost of the service model. The study will be carried out at five Field Days in Rift Valley and Central provinces.
Participants will not be tested for STI/HIV as part of this research; however, at their request, they may have received a test from the provider prior to the research interview. At the time of consent, they will have already received the test, so the consent form will not include anything specific to testing. In Kenya, all STI/HIV test results are reported to the national public health authorities. These reports are not used for contacting patients but for planning purposes.
Studietype
Studietype
Registrering (Faktiske)
Registrering
Kontakter og plasseringer
Studiesteder
-
-
Rift Valley & Central
-
Various, Rift Valley & Central, Kenya
- 5 Community Outreach Events
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:females aged 18-49 receiving health services at a field day event -
Exclusion Criteria:
-
Studieplan
Hvordan er studiet utformet?
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Health Services Research
Tidsramme: 1 year
|
Unmet need for family planning among women attending Field Days aged 18-49
|
1 year
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Health Services Research
Tidsramme: 1 year
|
Interest in receiving health services through Field Day model
|
1 year
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Samarbeidspartnere
Samarbeidspartnere
Etterforskere
Etterforskere
- Hovedetterforsker: John Bratt, MPP, MA, FHI 360
Studierekorddatoer
Studer hoveddatoer
Studiestart
Studiestart
Primær fullføring (Faktiske)
Primær fullføring
Studiet fullført (Faktiske)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
- AE-bivirkning
- AIDS ervervet immunsviktsyndrom
- ALT (SGPT) alaninaminotransferase
- ART antiretroviral terapi
- AST (SGOT) aspartataminotransferase
- DCF datainnsamlingsskjemaer
- DMC Dataovervåkingskomité
- FDA (U.S.) Food and Drug Administration
- GCP retningslinjer for god klinisk praksis
- HB sAg Hepatitt B overflateantigen
- ICH International Conference of Harmonization
- IND Investigational New Drug Application
- IRB Institutional Review Board
- IU internasjonale enheter
- mg milligram(er)
- mm3 kubikkmillimeter(r)
- PCR polymerase kjedereaksjon
- SAE alvorlig bivirkning
- µg mikrogram
- ULN øvre grense for normalområdet
- WB Western Blot
Andre studie-ID-numre
Andre studie-ID-numre
- 10227
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .